Cell line · CVCL_0036
Papers79
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 79
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| An MMP-14/STAT3 feedback loop upregulates PD-L1 to drive immunosuppression and tumorigenesis in bladder cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SESN2 promotes ferroptosis in bladder cancer by negatively regulating the NRF2/FSP1 signaling axis. | Transl Androl Urol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades. | Cancer Genomics Proteomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Antipsychotic Aripiprazole Induces Cytotoxicity in Bladder Cancer Cells While Preserving Urothelial and Bladder Function. | Pharmacol Res Perspect | 2026 | Its Methods give the RRID and name the line | PubMed | |
| O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The bladder cancer m6A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylation. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression. | Cell Oncol (Dordr) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mechanisms of Aristolochic Acid Resistance in Specialist Butterflies and Evolutionary Insights for Potential Protective Pathways. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial-Mesenchymal Transition Pathway. | Cancer Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| XPC Deficiency Activate Cisplatin-Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1-Mediated Ubiquitination of the p53 Protein. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin. | J Exp Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DGKα Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney Disease. | Cancer Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| VAX014 Activates Tumor-Intrinsic STING and RIG-I to Promote the Development of Antitumor Immunity. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Proteomic analysis of the urothelial cancer landscape. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0036/papers